[1]
Rapp UR, Goldsborough MD, Mark GE, Bonner TI, Groffen J, Reynolds FH Jr, Stephenson JR. Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proceedings of the National Academy of Sciences of the United States of America. 1983 Jul:80(14):4218-22
[PubMed PMID: 6308607]
[2]
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature. 2002 Jun 27:417(6892):949-54
[PubMed PMID: 12068308]
[3]
Lee B, Mukhi N, Liu D. Current management and novel agents for malignant melanoma. Journal of hematology & oncology. 2012 Feb 14:5():3. doi: 10.1186/1756-8722-5-3. Epub 2012 Feb 14
[PubMed PMID: 22333219]
[4]
Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D. BRAF mutation in papillary thyroid carcinoma. Journal of the National Cancer Institute. 2003 Apr 16:95(8):625-7
[PubMed PMID: 12697856]
[5]
Huang T, Zhuge J, Zhang WW. Sensitive detection of BRAF V600E mutation by Amplification Refractory Mutation System (ARMS)-PCR. Biomarker research. 2013 Jan 16:1(1):3. doi: 10.1186/2050-7771-1-3. Epub 2013 Jan 16
[PubMed PMID: 24252159]
[6]
Ziai J, Hui P. BRAF mutation testing in clinical practice. Expert review of molecular diagnostics. 2012 Mar:12(2):127-38. doi: 10.1586/erm.12.1. Epub
[PubMed PMID: 22369373]
[7]
Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW, Sykorova V. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013 Apr 10:309(14):1493-501. doi: 10.1001/jama.2013.3190. Epub
[PubMed PMID: 23571588]
[8]
Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Inhibition of mutated, activated BRAF in metastatic melanoma. The New England journal of medicine. 2010 Aug 26:363(9):809-19. doi: 10.1056/NEJMoa1002011. Epub
[PubMed PMID: 20818844]
[9]
Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. The New England journal of medicine. 2012 Feb 23:366(8):707-14. doi: 10.1056/NEJMoa1112302. Epub
[PubMed PMID: 22356324]
[10]
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England journal of medicine. 2011 Jun 30:364(26):2507-16. doi: 10.1056/NEJMoa1103782. Epub 2011 Jun 5
[PubMed PMID: 21639808]
[11]
Haroche J, Cohen-Aubart F, Emile JF, Maksud P, Drier A, Tolédano D, Barete S, Charlotte F, Cluzel P, Donadieu J, Benameur N, Grenier PA, Besnard S, Ory JP, Lifermann F, Idbaih A, Granel B, Graffin B, Hervier B, Arnaud L, Amoura Z. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Feb 10:33(5):411-8. doi: 10.1200/JCO.2014.57.1950. Epub 2014 Nov 24
[PubMed PMID: 25422482]
[12]
Planchard D, Kim TM, Mazieres J, Quoix E, Riely G, Barlesi F, Souquet PJ, Smit EF, Groen HJ, Kelly RJ, Cho BC, Socinski MA, Pandite L, Nase C, Ma B, D'Amelio A Jr, Mookerjee B, Curtis CM Jr, Johnson BE. Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. The Lancet. Oncology. 2016 May:17(5):642-50. doi: 10.1016/S1470-2045(16)00077-2. Epub 2016 Apr 11
[PubMed PMID: 27080216]
[13]
Tsai J,Lee JT,Wang W,Zhang J,Cho H,Mamo S,Bremer R,Gillette S,Kong J,Haass NK,Sproesser K,Li L,Smalley KS,Fong D,Zhu YL,Marimuthu A,Nguyen H,Lam B,Liu J,Cheung I,Rice J,Suzuki Y,Luu C,Settachatgul C,Shellooe R,Cantwell J,Kim SH,Schlessinger J,Zhang KY,West BL,Powell B,Habets G,Zhang C,Ibrahim PN,Hirth P,Artis DR,Herlyn M,Bollag G, Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proceedings of the National Academy of Sciences of the United States of America. 2008 Feb 26
[PubMed PMID: 18287029]
[14]
Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. The New England journal of medicine. 2014 Nov 13:371(20):1867-76. doi: 10.1056/NEJMoa1408868. Epub 2014 Sep 29
[PubMed PMID: 25265494]
[15]
Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010 Dec 16:468(7326):973-7. doi: 10.1038/nature09626. Epub 2010 Nov 24
[PubMed PMID: 21107323]
[16]
Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T. Cutaneous side-effects of kinase inhibitors and blocking antibodies. The Lancet. Oncology. 2005 Jul:6(7):491-500
[PubMed PMID: 15992698]
[17]
Carlos G, Anforth R, Clements A, Menzies AM, Carlino MS, Chou S, Fernandez-Peñas P. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. JAMA dermatology. 2015 Oct:151(10):1103-9. doi: 10.1001/jamadermatol.2015.1745. Epub
[PubMed PMID: 26200476]